Maricann Group (CNSX:MARI – Free Report) had its target price raised by National Bankshares from $13.25 to $15.00 in a research note released on Thursday,BayStreet.CA reports.
Separately, Royal Bank Of Canada boosted their price target on Maricann Group from $6.00 to $16.00 in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $14.10.
Check Out Our Latest Stock Report on MARI
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Further Reading
- Five stocks we like better than Maricann Group
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Another reason you need to own gold… [running out]
- Trump’s Final Shocking Act Begins February 24
- NEW: Gold makes history
- Become a 2x better options trader (in 2 days)
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
